Our prior studies of fused EndoP125A with an αHER2 antibody demonstrated superior anti-angiogenic and anti-tumor efficacy to αHER2 antibody alone, wild-type endostatin, or αHER2-fused to wild-type endostatin against HER2+ breast cancer xenografts [35,36]. This evidence concerns the gene COL18A1 and breast carcinoma.